earnings
confidence high
sentiment positive
materiality 0.80
Ceribell Q4 revenue $24.8M (+34% YoY); FY 2026 guidance $111-115M
Ceribell, Inc.
2025-FY EPS
reported -$1.46
vs consensus -$0.42
▼ miss
(-247.1%)
- Full-year 2025 revenue $89.1M (+36% YoY); net loss $53.4M ($1.46/share).
- Q4 gross margin 87%; active accounts 647; cash $159.3M.
- FY 2026 revenue guidance $111-115M, representing 25-29% growth.
- FDA 510(k) clearance for continuous delirium monitoring and neonatal seizure detection.
- FDA Breakthrough Device Designation for large vessel occlusion stroke detection solution.